Axoltis Pharma reports Phase 2 failure for experimental ALS drug

On September 15, 2026, French biotechnology company Axoltis Pharma announced that its Phase 2 clinical trial for an experimental amyotrophic lateral sclerosis (ALS) drug failed to meet its objectives. Despite the overall trial failure, the company indicated that it detected a small efficacy signal, suggesting potential pathways to move the experimental treatment forward in development.

Phase 2 ALS trial failure

• ▪Axoltis Pharma suggested that despite the Phase 2 clinical trial failure, a small signal was found to move the experimental amyotrophic lateral sclerosis drug forward.
• ▪The French biotechnology company Axoltis Pharma reported a Phase 2 clinical trial failure for its experimental amyotrophic lateral sclerosis drug on September 15, 2026.